Transgene and Institut Bergonié Present a Poster on the METROmaJX Trial (Oncolytic Virus Pexa-Vec + Metronomic Cyclophosphamide) at ESMO 2017 Congress

information fournie par Boursorama •07/09/2017 à 17:45

Strasbourg, France, September 7, 2017, 5:45 p.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops viral-based immunotherapies, announces that the results of the Phase 1 part of the METROmaJX trial will be presented in a poster presentation at the annual congress of European Society for Medical Oncology (ESMO) (8-12 September 2017, Madrid, Spain). These Phase 1 trial results showed that the regimen associating intravenous infusion of Pexa-Vec (JX-594) with low-dose cyclophosphamide was well-tolerated with no dose limiting toxicity in patients with solid tumors. Following these positive results, the Phase 2 part of the trial is currently enrolling patients with soft tissue sarcoma (STS) and HER2 negative-breast cancer.

Abstract title: A phase Ib trial of JX-594 (Pexa-Vec), a targeted multimechanistic oncolytic vaccinia virus, in combination with low-dose cyclophosphamide in patients with advanced solid tumors

• Poster number: 414P
• Date and time: 11 September 2017, 1:15 pm
• Location: Hall 8
• Presenter: Pr Antoine Italiano, MD, PhD (Institut Bergonié)

The abstract can be downloaded from the ESMO website and from Transgene’s website (www.transgene.fr).
.../...